Literature DB >> 30865017

Over-Utilization of Repeat Upper Endoscopy in Patients with Non-dysplastic Barrett's Esophagus: A Quality Registry Study.

Sachin Wani1, J Lucas Williams2, Srinadh Komanduri3, V Raman Muthusamy4, Nicholas J Shaheen5.   

Abstract

INTRODUCTION: Guidelines recommend that patients with non-dysplastic Barrett's esophagus (NDBE) undergo surveillance endoscopy every 3-5 years. Using a national registry, we assessed compliance to recommended surveillance intervals in patients with NDBE and identified factors associated with compliance.
METHODS: We analyzed data from the GI Quality Improvement Consortium registry. Data abstracted include procedure indication, demographics, endoscopy/pathology results, and recommendations for future endoscopy. Patients with an indication of Barrett's esophagus (BE) screening or surveillance, or an endoscopic finding of BE, with non-dysplastic intestinal metaplasia on pathological examination, were included. Compliance was defined as a recommendation to undergo subsequent endoscopy between 3 and 5 years. Multivariate logistic regression was conducted to assess variables associated with compliance.
RESULTS: Of 786,712 endoscopies assessed, 58,709 (7.5%) endoscopies in 53,541 patients met inclusion criteria (mean age 61.3 years, 60.4% men, 90.2% white, mean BE length was 2.3 cm). Most cases were performed by Gastroenterologists (92.3%) with propofol (78.7%). A total of 29,978 procedures (55.8%) resulted in pathology-confirmed BE. Among procedures with NDBE (n = 25,945), 29.9% were noncompliant with the 3-year threshold; most (26.9%) recommended surveillance at 1- to 2-year intervals. Patient factors such as extremes of age, black race, geographic region, type of sedation, and increasing BE length were associated with noncompliance. DISCUSSION: Approximately 30% of patients with NDBE are recommended to undergo surveillance endoscopy too soon. Patient factors associated with inappropriate utilization include extremes of age, black race, and increasing BE length. Compliance with appropriate endoscopic follow-up as a quality measure in BE is poor.

Entities:  

Mesh:

Year:  2019        PMID: 30865017     DOI: 10.14309/ajg.0000000000000184

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  10 in total

1.  Post-endoscopy Esophageal Neoplasia in Barrett's Esophagus: Consensus Statements From an International Expert Panel.

Authors:  Sachin Wani; Rena Yadlapati; Siddharth Singh; Tarek Sawas; David A Katzka
Journal:  Gastroenterology       Date:  2021-10-14       Impact factor: 22.682

Review 2.  Best Practices in Surveillance for Barrett's Esophagus.

Authors:  Joseph R Triggs; Gary W Falk
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-10-21

3.  The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management.

Authors:  Amir-Houshang Omidvari; Carlijn A M Roumans; Steffie K Naber; Sonja Kroep; Bas P L Wijnhoven; Ate van der Gaast; Pieter-Jan de Jonge; Manon C W Spaander; Iris Lansdorp-Vogelaar
Journal:  Am J Gastroenterol       Date:  2020-07       Impact factor: 10.864

4.  What is the optimal surveillance strategy for non-dysplastic Barrett's esophagus?

Authors:  Ying Gibbens; Prasad G Iyer
Journal:  Curr Treat Options Gastroenterol       Date:  2020-06-25

5.  TissueCypher Barrett's esophagus assay impacts clinical decisions in the management of patients with Barrett's esophagus.

Authors:  David L Diehl; Harshit S Khara; Nasir Akhtar; Rebecca J Critchley-Thorne
Journal:  Endosc Int Open       Date:  2021-02-18

6.  Attending Training Courses on Barrett's Esophagus Improves Adherence to Guidelines: A Survey from the Italian Society of Digestive Endoscopy.

Authors:  Rocco Maurizio Zagari; Leonardo Henry Eusebi; Giuseppe Galloro; Stefano Rabitti; Matteo Neri; Luigi Pasquale; Franco Bazzoli
Journal:  Dig Dis Sci       Date:  2020-09-28       Impact factor: 3.199

7.  Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists.

Authors:  Elissa M Ozanne; Elisabeth R Silver; Sameer D Saini; Joel H Rubenstein; Iris Lansdorp-Vogelaar; Nicole Bowers; Sarah Xinhui Tan; John M Inadomi; Chin Hur
Journal:  Am J Gastroenterol       Date:  2021-08-01       Impact factor: 12.045

Review 8.  Endoscopic eradication therapy for Barrett's oesophagus: state of the art.

Authors:  Jennifer M Kolb; Sachin Wani
Journal:  Curr Opin Gastroenterol       Date:  2020-07       Impact factor: 2.741

Review 9.  Role of Wide-Area Transepithelial Sampling With 3D Computer-Assisted Analysis in the Diagnosis and Management of Barrett's Esophagus.

Authors:  Robert D Odze; John Goldblum; Vivek Kaul
Journal:  Clin Transl Gastroenterol       Date:  2021-12-07       Impact factor: 4.488

10.  Independent Validation of a Tissue Systems Pathology Assay to Predict Future Progression in Nondysplastic Barrett's Esophagus: A Spatial-Temporal Analysis.

Authors:  Nicola F Frei; Kadère Konte; Emily A Bossart; Katelyn Stebbins; Yi Zhang; Roos E Pouw; Rebecca J Critchley-Thorne; Jacques J G H M Bergman
Journal:  Clin Transl Gastroenterol       Date:  2020-10       Impact factor: 4.396

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.